Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avacta GroupAVCTF 23 3-Year Book Growth Rate is -57.80% as of Dec. 2025. GuruFocus rates AVCTF with a GF Score™ of 23/100 and a GF Value™ of $0.65 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,131 Biotechnology companies, Avacta Group ranks worse than 90.54% on this metric.
During the past 12 months, Avacta Group's average Book Value per Share Growth Rate was -76.00% per year.
During the past 3 years, the average Book Value per Share Growth Rate was -57.80% per year.
During the past 5 years, the average Book Value per Share Growth Rate was -50.30% per year.
During the past 10 years, the average Book Value per Share Growth Rate was -33.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Avacta Group was 271.90% per year. The lowest was -57.80% per year. And the median was -9.95% per year.
Avacta Group (OTCPK:AVCTF) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Avacta Group 3-Year Book Growth Rate Related Terms
AVCTF vs VRTX, REGN, RVMD: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Avacta Group's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avacta Group 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avacta Group's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Avacta Group's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of -57.80% mean?
Avacta Group (AVCTF) has a 3-Year Book Growth Rate of -57.80% as of Dec. 2025. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Avacta Group and its competitors. According to the industry distribution chart, Avacta Group ranks #1024 out of 1131 companies in the Biotechnology industry, placing it in the top 90.5%.
Is Avacta Group's 3-Year Book Growth Rate too high?
Avacta Group's current 3-Year Book Growth Rate is -57.80%. Based on the distribution chart, Avacta Group ranks #1024 out of 1131 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avacta Group has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avacta Group's 3-Year Book Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avacta Group ranks #1024 out of 1131 companies for 3-Year Book Growth Rate. This places Avacta Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Avacta Group and its competitors. Avacta Group's current 3-Year Book Growth Rate is -57.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avacta Group stock overvalued right now?
Based on GuruFocus' analysis, Avacta Group (AVCTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.65, compared to a current price of $0.94 — trading 43.9% above its estimated fair value. The current 3-Year Book Growth Rate is -57.80%. Avacta Group's overall GF Score™ is 23/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Avacta Group (AVCTF), the current 3-Year Book Growth Rate is -57.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avacta Group (AVCTF) Overvalued in 2026?
Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued.
The current stock price of $0.94 is trading 43.9% above its estimated GF Value™ of $0.65.
GuruFocus considers Avacta Group to be Significantly Overvalued.
Key valuation signals for AVCTF:
3-Year Book Growth Rate: -57.80%
GF Value™: $0.65 vs. price of $0.94 (43.9% above fair value)
No single metric tells the full story. See the AVCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
23GF Score
Get the complete analysis for AVCTF
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVCTF has been successfully added to your 
